ARTICLE

IN VITRO BIOEQUIVALENCE FOR PULMONARY AND NASAL DELIVERY

Abstract

ONdrugDelivery Issue No 102, November 11th, 2019
PULMONARY & NASAL DELIVERY

With a focus on bioequivalence testing in the development of generic inhalables, Mark Parry, Technical Director, Intertek Melbourn, highlights some of the shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques that Intertek offers to allow its clients to de-risk clinical studies or even to support robustly in vitro data submissions as to avoid clinical work.

Click the button below to download the full article.

DOWNLOAD ARTICLE

Tel: +44 161 721 5247 • Email: bd.melbourn@intertek.com • intertek.com/pharmaceutical